HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes.

Int Immunol. 1999 Aug;11(8):1351-6. Unique Identifier : AIDSLINE MED/99352265
Le Gal FA; Riteau B; Sedlik C; Khalil-Daher I; Menier C; Dausset J; Guillet JG; Carosella ED; Rouas-Freiss N; Laboratoire d'Immunologie des Pathologies Infectieuses et; Tumorales, INSERM U445, Institut Cochin de Genetique; Moleculaire, 27, rue du Faubourg St Jacques, Universite Rene; Descartes, 75014 Paris, France.

Abstract: In the present study, we demonstrate that the non-classical MHC class I molecule HLA-G impairs specific cytolytic T cell functions in addition to its well-established inhibition of NK lysis. The antigen-specific cytotoxic T lymphocyte (CTL) response analyzed was mediated by CD8(+) T cells specific for the influenza virus matrix epitope, M58-66, presented by HLA-A2. The transfection of HLA-G1 cDNA in target cells carrying the M58-66 epitope reduced their lysis by these virus-specific CTL. This HLA-G-mediated inhibition of antigen-specific CTL lysis was (i) peptide dose dependent, (ii) reversed by blocking HLA-G with a specific mAb and (iii) still observed despite the blockade of HLA-E/CD94/NKG2A interaction. By inhibiting both CTL and NK functions, HLA-G appears to have an extensive role in immune tolerance.

Keywords: JOURNAL ARTICLE Blotting, Western Cytotoxicity Tests, Immunologic CD8-Positive T-Lymphocytes/IMMUNOLOGY Epitopes Flow Cytometry Histocompatibility Antigens Class I/*IMMUNOLOGY Human HLA Antigens/*IMMUNOLOGY Immune Tolerance Influenza A Virus, Human/CHEMISTRY/*IMMUNOLOGY Killer Cells, Natural/*IMMUNOLOGY Peptide Fragments/*IMMUNOLOGY Receptors, Immunologic/IMMUNOLOGY/METABOLISM T-Lymphocytes, Cytotoxic/*IMMUNOLOGY Tumor Cells, Cultured Viral Matrix Proteins/*IMMUNOLOGY
991230
A99C1071

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .